Intel Confirms 12 P-Core Bartlett Lake S CPU In Nova Lake Slide
Intel has given the first confirmation of the long-rumored Bartlett Lake CPU with 12 performance cores and no E cores. The surprise reveal comes in a slide about Intel's Time Coordinated Computing platform, which pushes high-performance edge computing. The document is designed to show how Intel's CPUs can manage real-time and general-purpose workloads simultaneously, showing current and future-generation CPUs that can do this. One of them is a 12-core Bartlett Lake design.
Intel's desktop platforms have been rather uninspiring for the past few generations. The 14th Generation was barely a clock-speed increase over its predecessor, and saw very little movement between generations, especially with the flagship. The Arrow Lake generation that followed improved performance per watt and productivity workloads, but did little for gaming. Bartlett Lake is slotting somewhere in the middle, supporting the older socket design, but with a performance focus.
Long-rumored as more of a competitor for AMD's gaming-focused X3D CPUs, the 12-core Bartlett Lake CPU is unique among Intel's existing designs since it has just one CPU core architecture onboard. It uses just performance cores, whereas all other Intel CPUs from the past few generations have offered either a small quantity of solo P cores, or a mixture of performance and efficiency (and sometimes low-power efficiency) cores.
Credit: Intel
The lack of any E cores will absolutely tank this chip's multithreading performance. But Intel's performance cores have long been impressively powerful, just hampered by their limited number and high power draw compared with AMD's alternatives. A 12-core Bartlett Lake CPU could end up being Intel's gaming performance king for a short time ahead of an Arrow Lake refresh later this year, or provide an alternative to older CPU generations like AMD's still-supported Ryzen 5000 series.
No more details about the chip exist at this time, with this slide reveal being the first to even confirm its existence. It debuts on this slide alongside more established upcoming CPU generations, like Panther Lake and Nova Lake, with both performance S and efficient, U versions of the chips.
Intel also gave the first lip-service to a generation of low-power chips called Wildcat Lake, which VideoCardz suggests as a probable successor for Twin Lake.
Don't want to wait for Bartlett Lake or any other CPU launches? Here are the best CPU deals available right now.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
31 minutes ago
- New York Post
Ozempic makes you twice as likely to develop this debilitating condition — what that really means for your risk
A growing number of Ozempic and Mounjaro users have shared stark warnings after going blind while using GLP-1 drugs. Now a new study is bringing into focus the relationship between diabetic GLP-1 users and the elevated risk of age-related eye disease. But despite seemingly alarming numbers, a doctor explained to The Post why she doesn't actually think it should steer people away from the jab. 3 A 2024 study found that 12% of the US population has taken a GLP-1 drug at some point, with around 6% currently using them. alones – Published in JAMA Ophthalmology, the study was drawn from the health records of nearly 140,000 patients. Researchers found that after one year, GLP-1 users were more than twice as likely to develop neovascular age-related macular degeneration than those who were not taking the drugs. Age-related macular degeneration (AMD) is a disease that gradually damages the macula, the part of your eye's retina responsible for sharp, central vision. As it worsens, people find it increasingly difficult to see things directly in front of them, while their peripheral vision remains largely unaffected. In older people, AMD is a leading cause of irreversible blindness. The study found the risk percentage was 0.2% in GLP-1 users and 0.1% in nonusers. Nearly 20 million adults in the US are living with AMD, which comes in two types. The slower-moving dry AMD makes up about 80% of cases. It occurs when the macula gets thinner with age, often due to the buildup of yellow protein deposits known as drusen, according to the American Academy of Ophthalmology. Wet AMD, also known as neovascular AMD (nAMD), while less common, is far more aggressive, causing rapid and severe vision loss. In this form, the macula's function is compromised by the growth and leakage of abnormal blood vessels beneath the retina. The condition is typically treated with frequent injections to restore or stabilize vision. 3 Kaden notes that while there is cause for concern, headlines will amplify what she believes is a relatively low risk Northwell Foundation 'What researchers in this latest study were looking for specifically was whether or not these were people who converted from the dry form of macular degeneration, which is where you don't have abnormal blood vessels to the wet form, which is when you do,' Dr. Talia Kaden, director of the Northwell Health retina fellowship told the Post. But Kaden noted that while there is cause for concern, she actually believes there a relatively low risk. 'We're talking about a handful of patients who might have an increase in retinopathy compared to the millions of patients on these medications.' Dr. Talia Kaden 'That 2X number is really powerful, but when you look at the raw data, I don't think it's quite as strong a punch. I don't think that number should be a reason for people not to be on these drugs. I do think, though, it is worth continuing to look into,' she said. This study adds to a growing body of research documenting vision problems in patients using GLP-1 drugs. A review published earlier this year in JAMA Ophthalmology uncovered at least nine cases of patients who experienced vision loss after taking semaglutide or tirzepatide, the active ingredients in Wegovy and Zepbound, respectively. And a 2024 study suggested a potential link between semaglutide and the rare eye condition nonarteritic anterior ischemic optic neuropathy (NAION), in which restricted blood flow to the optic nerve causes sudden-onset vision loss. 'None of these studies are definitive in identifying that there has been a change. Some of them show a slight increase, but we're talking about a handful of patients who might have an increase in retinopathy compared to the millions of patients on these medications,' Kaden said. 3 In older people, AMD is a leading cause of irreversible blindness. StockPhotoPro – Researchers think that declining blood glucose levels caused by GLP-1s could trigger abnormal blood vessel growth in the retina. Further, there are GLP-1 receptors in the retina, and these drugs increase the levels of molecules that lead to harmful blood vessel formation. 'Seeing such a clear signal in our study was striking,' co-author Reut Shor of the University of Toronto told STAT. 'The absolute risk remains low, but the advanced form of AMD is a condition with serious implications for vision and quality of life. So a doubling of risk is clinically meaningful, particularly for vulnerable populations like older adults who may already be at elevated baseline risk.' Shor and his team note that more research is necessary to determine whether direct or indirect effects are causing the increased risk of nAMD. Shor and Kaden maintain that these findings should not be cause for alarm nor a reason to halt the prescription or use of these medications; rather, patients should be made aware of the risk and monitor their vision accordingly. Kaden, the study authors, and other experts recommend that GLP-1 users be on the lookout for any vision changes that could indicate early signs of AMD. 'We really want you to look for anything blurring, any new distortion. If you're looking at a flagpole or a doorframe, that should be a straight line. If all of a sudden that line looks wavy or curvy, that's a reason to seek a consultation with a retina specialist,' said Kaden.
TechCrunch
42 minutes ago
- TechCrunch
AMD acqui-hires the employees behind Untether AI
In Brief AMD is continuing its acquisition spree. Semiconductor giant AMD acqui-hired the team behind Untether AI, a startup that develops AI inference chips, as originally reported by CRN. Untether claims that their chips are faster and more energy-efficient than their rivals. The terms of the deal weren't disclosed. Toronto-based Untether was founded in 2018 and has raised more than $150 million in venture capital from firms including Intel Capital, Radical Ventures, and Tracker Capital Management, among others. Untether released an AI chip in October meant to power physical AI applications in machines including cars and agricultural devices. Earlier this week, AMD announced it had acquired AI software optimization platform Brium. TechCrunch has reached out to AMD for more information.
Yahoo
an hour ago
- Yahoo
Nvidia Secures 92% GPU Market Share in Q1 2025
Nvidia (NVDA, Financials) captured a dominant 92% share of the add-in-board GPU market in the first quarter of 2025, extending its lead over rivals Advanced Micro Devices (AMD, Financials) and Intel (INTC, Financials), according to Jon Peddie Research. Warning! GuruFocus has detected 4 Warning Signs with NVDA. Revenue and shipment figures from the PC GPU market show Nvidia expanded its AIB market share by 8.5 percentage points quarter over quarter, while AMD dropped 7.3 percentage points to 8%. Intel fell to 0% after a 1.2-point decline. The total AIB market shipped 9.2 million units in Q1. The companys growth was driven by the launch of its RTX 50 series GPUs, while AMDs RDNA 4 launch came later in the quarter. Intels Battlemage B-series failed to move the needle, per the data. In the overall PC GPU spaceincluding integrated graphicsNvidia also gained 3.6 percentage points, outperforming AMD and Intel, who posted respective declines of 1.6 and 2.1 points. Demand from gamers remains concentrated on the RTX 3060 and 4060, according to Steams May 2025 hardware survey, though the new 5060 Ti has started to appear with a 0.21% share. The strength in discrete GPUs contrasts with a broader slowdown in the desktop CPU market, which shrank by 14.5% year over year and 20.6% quarter over quarter. However, data center GPU shipments rose 9.6%, reflecting ongoing AI-driven demand. The discrete GPU market is expected to face a -10.3% CAGR through 2028, with Jon Peddie Research projecting an installed base of 130 million units by the end of the forecast period. By 2028, PC GPUs are expected to total 2.8 billion units, with dedicated GPUs reaching 15% penetration. This article first appeared on GuruFocus.
